- Investigational, novel eye drop candidate was assigned PDUFA goal date of October 22, 2023 PONTE VEDRA, Fla., Feb. 21, 2023 /PRNewswire/ -- Orasis Pharmaceuticals, an emerging ophthalmic ...

Neonatal alloimmune neutropenia is due to maternal production of antibodies directed against neutrophil specific antigens (NA1, NA2, NB1, NC1) reacting with fetal-neonatal and paternal neutrophils.

INDIANAPOLIS, June 27, 2023 /PRNewswire/ -- Roche today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys ® Total-Tau CSF assays (tTau) have received U.S. Food and Drug ...

In this Innovation Spotlight, Dan Levangie, president and chief executive officer of CereVasc, discusses a new treatment strategy for NPH using an endovascularly implantable CSF shunt that minimizes ...

Jason Jardine, Makoto Tsunozaki Ph.D. On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody, NIKTIMVO ...

- Presbyopia is the loss of ability to focus on near objects as a result of the natural aging process and affects more than 120 million people in the U.S. - Phase 3 NEAR-1 and NEAR-2 clinical trials, ...

Relationship Between ERCC1 Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage ...

A study published in the Journal of Cannabis Research examined the effect of granulocyte colony-stimulating factor (G-CSF) on brain recovery following traumatic brain injury (TBI). The findings showed ...

Patients with liver failure could benefit from a treatment that helps the immune system to combat infections linked to the condition, research suggests. A study in mice has revealed that treatment ...